Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Meditation app aims to boost sleep and ease stress in aging brains

NCT ID NCT06633978

Symptom relief Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 25, 2026 · Updated 3 times

Summary

This pilot study tests whether a personalized digital meditation app called MediTrain can help older adults with mild cognitive impairment (MCI) sleep better and feel less stressed. Participants will use the app for 30 minutes daily over 6 weeks. Researchers will measure changes in attention, sleep quality, and stress responses, with some participants followed for 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MediTrain digital meditation app
What this could lead to
If it works, this could point toward a simple, non-drug way to improve sleep and reduce stress in people with mild cognitive impairment.
What could go wrong
This is a small, early pilot study with only 90 participants. Results may not apply to everyone, and the app may not provide lasting benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* comfortably ambulatory healthy physical condition * normal or corrected to normal visual * auditory acuity * fluency in spoken English * Between 60-85 years old * No neurological or psychiatric disorders * No substance abuse * Not taking anti-depressants * Not taking anti-anxiety medication * No history of seizures * No color blindness * No glaucoma * No macular degeneration * No amblyopia (lazy eye) * No strabismus (cross eyed) * Aneurysm clip(s) * No Cardiac pacemaker * No Implanted cardioverter defibrillator (ICD) * No Electronic implant or device * No Magnetically-activated implant or device * No Neurostimulation system * No Spinal cord stimulator * No Internal electrodes or wires * No Bone growth/bone fusion stimulator * No Cochlear, otologic, or other ear implant * No Insulin or other infusion pump * No Implanted drug infusion device * No type of prosthesis (eye, penile, etc.) * No Heart valve prosthesis * No Eyelid spring or wire * No Artificial or prosthetic limb * No Metallic stent, filter, or coil * No Shunt (spinal or intraventricular) * No Vascular access port and/or catheter * No Radiation seeds or implants * No Swan-Ganz or thermodilution catheter * No Medication patch (Nicotine, Nitroglycerine) * No metallic fragment or metallic foreign body in/on the body that can not be removed * No Wire mesh implant * No Tissue expander (e.g., breast) * No Surgical staples, clips, or metallic sutures * No Joint replacement (hip, knee, etc.) * No Bone/joint pin, screw, nail, wire, plate, etc. * No IUD, diaphragm, or pessary * No Dentures or partial plates that can not be removed * No Tattoo or permanent makeup * No Body piercing jewelry * No Claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging MCI

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.